Senti Biosciences went public via merger with Dynamics Special Purpose in a $601m deal.

Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, went public via merger with Dynamics Special Purpose, a special purpose acquisition company, in a $601m deal. The deal involved a $66m financing from institutional investors including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, LifeForce Capital, NEA, Parker Institute for Cancer Immunotherapy, and T. Rowe Price. "Humans have always sought medicines that can treat illnesses with more precision, efficacy, and safety. However, existing drugs are still unable to match the complexity of many diseases, such as cancer and beyond. With recent advances in synthetic biology, computation, and massive biological data generation, I believe that we have a unique opportunity to engineer intelligent cell and gene therapies that directly tackle the heterogeneity and dynamic nature of disease, which have the potential to fundamentally transform our therapeutic arsenal," Tim Lu, Senti Bio CEO.